Anti-chrondrosarcoma compounds

Details Anti-chrondrosarcoma compounds Anti-chrondrosarcoma compounds

2007-03-13

2007-03-13

Tsang, Cecilia J. (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S002600, C514S012200, C514S013800, C530S326000, C530S328000

Reexamination Certificate

active

10601059

ABSTRACT:
The invention provides inhibitors of chondrosarcoma cell growth that are useful as anti-cancer and anti-tumor agents. The inhibitors are peptides having sequences related to cleavage regions of the proenzyme forms of matrix metalloproteinases and that can inhibit the activity of matrix metalloproteinases. The peptide inhibitors of the invention can be formulated into therapeutic compositions, lotions, creams and wound dressings.

REFERENCES:
patent: 4424552 (1984-01-01), Marcoux
patent: 5270447 (1993-12-01), Liotta et al.
patent: 5280106 (1994-01-01), Liotta et al.
patent: 5372809 (1994-12-01), Liotta et al.
patent: 5585356 (1996-12-01), Liotta et al.
patent: 5698671 (1997-12-01), Stetler-Stevenson et al.
patent: 5770691 (1998-06-01), Fields et al.
patent: 5811252 (1998-09-01), Verheijen
patent: 5869277 (1999-02-01), Stetler-Stevenson et al.
patent: 6043087 (2000-03-01), Bini et al.
patent: 6127139 (2000-10-01), Te Koppele et al.
patent: 6184022 (2001-02-01), Seiki et al.
patent: 6191225 (2001-02-01), Barkac et al.
patent: 6204043 (2001-03-01), Shapiro
patent: H1973 (2001-07-01), Hu
patent: 6274703 (2001-08-01), Goldberg
patent: 6399371 (2002-06-01), Falduto et al.
patent: 6482802 (2002-11-01), Hu et al.
patent: 6753310 (2004-06-01), Oku et al.
patent: 6812339 (2004-11-01), Venter et al.
patent: 6906036 (2005-06-01), Quirk et al.
patent: 2001/0016333 (2001-08-01), Seiki et al.
patent: 2001/0031478 (2001-10-01), Bronstein et al.
patent: 2002/0099004 (2002-07-01), Lund et al.
patent: 2003/0012794 (2003-01-01), Srivastava et al.
patent: 2003/0096757 (2003-05-01), Quirk et al.
patent: 2003/0148959 (2003-08-01), Quirk et al.
patent: 2003/0166567 (2003-09-01), Quirk et al.
patent: 2003/0199440 (2003-10-01), Dack et al.
patent: 2004/0010001 (2004-01-01), Au et al.
patent: 2005/0239710 (2005-10-01), Quirk et al.
patent: 1549722 (2004-11-01), None
patent: 0917165 (1999-05-01), None
patent: 06213888 (1994-05-01), None
patent: 06300757 (1994-10-01), None
patent: 07159402 (1995-06-01), None
patent: 07-303482 (1995-11-01), None
patent: 07-330795 (1995-12-01), None
patent: 08134098 (1996-05-01), None
patent: 08136548 (1996-05-01), None
patent: 08217800 (1996-08-01), None
patent: 09023889 (1997-01-01), None
patent: 09084589 (1997-03-01), None
patent: 09087299 (1997-03-01), None
patent: 09136841 (1997-05-01), None
patent: 09206099 (1997-08-01), None
patent: 09249700 (1997-09-01), None
patent: 10210982 (1998-08-01), None
patent: 10287700 (1998-10-01), None
patent: 10313896 (1998-12-01), None
patent: 2000270874 (2000-10-01), None
patent: 2001011093 (2001-01-01), None
patent: 2001-072589 (2001-03-01), None
patent: WO-90/10228 (1990-09-01), None
patent: WO-90/10228 (1990-09-01), None
patent: WO-94/10208 (1994-05-01), None
patent: WO-95/02045 (1995-01-01), None
patent: WO-95/15374 (1995-06-01), None
patent: WO-96/18725 (1997-06-01), None
patent: WO-97/25437 (1997-07-01), None
patent: WO-98/04287 (1998-02-01), None
patent: WO-98/12309 (1998-03-01), None
patent: WO-98/31818 (1998-07-01), None
patent: WO-98/40475 (1998-09-01), None
patent: WO-98/42865 (1998-10-01), None
patent: WO-99/05261 (1999-02-01), None
patent: WO-99/31969 (1999-07-01), None
patent: WO-98/34641 (1999-08-01), None
patent: WO-99/58126 (1999-11-01), None
patent: WO-99/65519 (1999-12-01), None
patent: WO-00/20860 (2000-04-01), None
patent: WO-00/53219 (2000-09-01), None
patent: WO-00/74634 (2000-12-01), None
patent: WO-01/10437 (2001-02-01), None
patent: WO-01/13937 (2001-03-01), None
patent: WO-0126671 (2001-04-01), None
patent: WO-01/38558 (2001-05-01), None
patent: WO-01/54723 (2001-08-01), None
patent: WO-01/62206 (2001-08-01), None
patent: WO-01/62261 (2001-08-01), None
patent: WO-00/63227 (2001-10-01), None
patent: WO-03/018748 (2003-03-01), None
Agren, Magnus S., “Matrix metalloproteinases (MMPs) are required for re-epitheliazation of cutaneous wounds”,Archives Dermatol. Res., 291, (1999), 583-590.
Attie, Kenneth M., “Genetic studies in idiopathic short stature”,Current Opinion in Pediatrics, 12, (2000), 400-404.
Azzam, H. S., et al., “Association of MMP-2 activation potential with metastatic progression in human breast cancer cell lines independent of .MMP-2 production”,J. Natl. Cancer Inst., 85 (21), (1993),1758-1764.
Baker, E. A., et al., “Proteinases, their inhibitors, and cytokine profiles in acute wound fluid”,Wound Repair Regen., 8 (5), (2000), 392-398.
Becker, Joseph W., “Stromelysin-1: Three-dimensional structure of the inhibited catalytic domain and of the C-truncated proenzyme”,Protein Science, 4, (1995), 1966-1976.
Berend, Keith R., et al., “Association between ratio of matrix metalloproteinase-1 to tissue inhibitor of metalloproteinase-1 and local recurrence, metastasis, and survival in human chondrosarcoma”,Journal of Bone&Joint Surgery—Americanvol. 80(1), (1999), 893-895.
Bhide, V. M., et al., “Use of a fluorogenic septapeptide matrix metalloproteinase assay to assess responses to periodontal treatment”,J. Periodontol., 71(5), (2000), 690-700.
Bickett, D. M., et al., “A high throughput fluorogenic substrate for interstitial collagenase (MMP-1) and gelatinase (MMP-9)”,Anal. Biochem., 212 (1), (1993), 58-64.
Bickett, D. M., et al., “A high throughput fluorogenic substrate for stromelysin (MMP-3)”,Ann. N Y Acad. Sci., 732, (1994), 351-355.
Blaschke, Rudiger J., et al., “SHOX: Growth, Leri-Weill and Turner Syndromes”,TEM, 11, (2000), 227-230.
Bremer, C., et al., “In Vivo molecular toarget assessment or matrix metaloproteinase inhibition”,Nat. Med., 7 (6), (2001), 743-748.
Brown, P. D., et al., “Cellular activation of the 72 kDa type IV procollagenase/TIMP-2 complex”,Kidney Int., 43 (1), (1993), 163-170.
Brown, Rebeccah L., et al., “PDGF and TGF-a Act Synergistically to Improve Wound Healing in the Genetically Diabetic Mouse”,Journal of Surgical Research, 56, (1994), 562-570.
Browner, Michelle F., “Matrilysin-Inhibitor Complexes: Common Themes among Metalloproteases”,Biochemistry, 34, (1995), 6602-6610.
Cabrele, Chiara, et al., “Y-receptor affinity modulation by the design of pancreatic . . . ”,Peptides, 22, (2001), 365-378.
Calabrese, Edward J., “Cell Migration / Chemotaxis: Biphasic Dose Responses”,Critical Reviews in Toxicology, 31 (4&5), (2001), 615-624.
Calvin, Melissa, “Cutaneous Wound Repair”,Wounds: A Compendium of Clinical Research and Practice, 10 (1), (1998), 12-32.
Chen, L. C., et al., “Disruption of the cysteine-75 and zinc ion coordinatin is not sufficient to activate the precursor of human matrix metalloproteinase 3 (stromelysin 1)”,Biochemistry, 32 (39), (1993), 10289-10295.
Chi, Yeon Sook, et al., “Effects of the Chestnut Inner Shell Extract on the Expression of Adhesin Molecules, Fibronectin and Vitronectin, of Skin Fibroblasts in Culture”,Archives of Pharmacal Research, 25 (4), (2002), 469-474.
Chin, Jason W., et al., “Concerted Evolution of Structureand Function in a Miniature Protein”,J. Am. Chem. Soc., (2001), 2929-2930.
Chin, Jason W., et al., “Methodology for Optimizing Functional Miniature Proteins Based on Avian Pancreatic Polypeptide Using Phage Display”,Bioorganic&Medicinal Chemistry Letters, 1, (2001), 1501-1505.
Clark, Richard A., “Wound Repair”,The Molecular and Cellular Bilogy of Wound Repair—2nd ed., Plenum Press, NY,(1995), 3-50.
Colandrea, Teresa Di, “Epidermal Expression of Collagenase Delays Wound-Healing in Transgenic Mice”,The Journal of Investigative Dermatology, (1998), 1029-1033.
Duivenvoorden, Wilhelmina C., “Use of Tetracycline as an Inhiitor of Matrix Metalloproteinase Activity Secreted by Human Bone-Metastasizing Cancer Cells”,Invasion Metastasis, 17, (1997), 312-322.
Duncan, M. E., et al., “Human matrix metalloproteinase-9: activation by limited trypsin”, Eur. J. Biochem., 258 (1), (1998), 37-43.
F

Affiliated with

Also associated with

Rating

Anti-chrondrosarcoma compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Anti-chrondrosarcoma compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-chrondrosarcoma compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3802813